Fusion Antibodies News
Dr McGirr named ‘Future Innovator’ Winner at KTP Best of the Best Awards
Dr Leona McGirr of Fusion Antibodies has received a top honour at the annual celebration of the most outstanding Knowledge Transfer Partnership (KTP) Projects.
Fusion Antibodies collaborates with QUB Led Project in Multi-Million Pound Funding Bid
A Belfast-based bid led by Queens University Belfast (QUB), is the only bid from Northern Ireland to be selected for the next stage of the UK Research and Innovation’s Strength in Places Fund (SIPF).
Fusion Antibodies make key Covid-19 Reagents available
As part of our efforts to combat the Covid-19 pandemic, We have designed and expressed a panel of unique recombinant protein antigens to assist in the search for a neutralising therapeutic antibody against SARS-CoV 2.
Fusion Antibodies partner with BioTickle to deliver antibody development services in India
Fusion Antibodies have named BioTickle as their exclusive distributor in India to provide access to proprietary antibody discovery, engineering and cell line development technologies.
Research Alliance with Queen’s University Belfast
A new research alliance has been formed to seek new therapeutic and diagnostic approaches to help in the global fight against the coronavirus pandemic.
Fusion Antibodies Collaborates with Queen’s University on Knowledge Transfer Partnership Programme
The new programme will allow for the development of an innovative software solution for the design of antibody libraries.
Fusion Antibodies form strategic collaboration with E2DG to provide end-to-end service for oncology drug discovery companies.
The two companies will work together to deliver a seamless service offering for clients from discovery to manufacturing and PoC preclinical and phase I & II design and execution.
Fusion Antibodies partner with Erada to develop ground breaking Malaria diagnostic
Ground Breaking New Saliva Diagnostic Test Set to Help Eliminate Malaria.
Fusion Antibodies to collaborate with Analytics Engines
Fusion Antibodies plc, experts in antibody engineering and Analytics Engines, an advanced data analytics company, have announced a strategic collaboration to incorporate machine learning (ML) and artificial intelligence (AI) into Fusion Antibodies’ CDRx™ humanization platform.
Fusion Antibodies announces partnership with Protein Alternatives
Fusion Antibodies announces partnership with Protein Alternatives to develop world class humanized antibodies for therapeutic development
Fusion Antibodies plc, a UK-based contract research organisation…
Funding for Queen’s pancreatic cancer drug research in collaboration with Fusion Antibodies
Queen’s University Belfast researchers at the Centre for Cancer Research and Cell Biology (CCRCB) alongside Fusion Antibodies plc have secured a prestigious Medical Research Council (MRC) award to develop a new antibody drug for the treatment of pancreatic cancer.
Alliance between Fusion Antibodies and Nb Health Laboratory
Fusion Antibodies, a UK-based contract research organisation and NB Health Laboratory (NBHL), a Japan-based biotechnology company specialising in GPCR-targeting drug discovery, are entering an alliance for a research and licence agreement in…